Monday, 6th JULY 2026: ‘Your Gateway to Aesthetics: A Step-by-Step Introduction for NHS Clinicians’
WEDNESDAY, 1ST JULY 2026: ‘Your Gateway to Aesthetics: A Step-by-Step Introduction for NHS Clinicians’
Monday, 6th JULY 2026: ‘Your Gateway to Aesthetics: A Step-by-Step Introduction for NHS Clinicians’
WEDNESDAY, 1ST JULY 2026: ‘Your Gateway to Aesthetics: A Step-by-Step Introduction for NHS Clinicians’
| 🎓 Learn to assess every patient with the clinical confidence to match treatment to pathology: Explore Courses | Free Upcoming Webinar | Book a Course Enquiry Call |
One of the most clinically significant skills in aesthetic medicine is knowing when not to inject. As the range of injectable treatments has expanded — HA fillers, biostimulators, neurotoxins, skin boosters, polynucleotides — so too has the temptation to reach for a non-surgical solution for every patient who walks through the door.
But the ageing face is a multilayer structure, and not all its changes are amenable to injectable correction. Some presentations are structural and mechanical in nature, requiring surgical repositioning of tissue that no volume of filler will replicate.
Being able to distinguish between a patient whose signs of ageing are primarily volumetric — and therefore injectable-appropriate — and one who has significant ligament laxity and skin redundancy requiring surgical intervention is not just good practice; it is an ethical and medicolegal responsibility. As Fitzgerald and Graivier et al. (2010) observe, surgical and non-surgical modalities are complementary, not competing, and the most sophisticated practitioners understand how and when to deploy each. Patients who receive the wrong treatment for their presenting pathology — whether under- or over-treated — will not achieve their goals, and may be harder to treat surgically later.
This blog provides a clinically grounded framework for assessing the ageing face, recognising the features that indicate surgical candidacy, and identifying presentations where injectables remain the treatment of first choice. For training in comprehensive facial assessment and treatment planning, explore Acquisition Aesthetics courses.
Facial ageing is not a single process — it is the simultaneous progression of changes across every tissue layer, each occurring at a different rate and with different clinical implications. Understanding which layer has aged most in a given patient determines what that patient needs.
Mendelson and Wong (2012), in their comprehensive review of craniofacial skeletal changes with ageing, demonstrated that specific areas of the facial skeleton undergo progressive resorption over time. The maxilla retrudes, the piriform aperture enlarges, the orbital rim recedes, and the prejowl area of the mandible loses definition. These skeletal changes affect the structural foundation on which all overlying soft tissue rests.
Critically, skeletal resorption in the midface — particularly the maxilla and orbital rim — creates the appearance of volume deficit and periorbital hollowing that is, in part, a bony change rather than a soft tissue change. Addressing these with filler at the appropriate structural layer (deep supraperiosteal) is therefore anatomically sound. Conversely, skeletal changes in the mandible can contribute to jowling and loss of lower face definition, where a purely volumetric approach may not replicate the support that has been lost.
The face is held in its youthful position by a network of retaining ligaments that attach the skin and superficial soft tissue to deeper structures and bone. With ageing, these ligaments attenuate, allowing the soft tissue envelope to descend. The clinical result is predictable: deepening of the nasolabial fold, descent of the malar fat pad, jowling along the mandibular border, and neck laxity. These are positional changes — tissue that has moved, not disappeared. Volume alone will not correct them.
Lambros (2007), in his influential photographic analysis comparing individuals over up to 50 years, challenged the purely gravitational model of facial ageing. His work demonstrated that the lid-cheek junction remained largely stable in position over time, and that the appearance of descent was substantially attributable to volume loss — deflation of specific fat compartments — rather than pure descent. This evidence underpins the rational use of volumetric filler in the midface and periorbital region.
In practice, both mechanisms operate concurrently: volume is lost and tissue descends. The relative contribution of each determines whether volume restoration, mechanical lifting (surgical or energy-based), or a combination is the correct approach for any given patient.
Dermal thinning, elastosis, photoageing, and progressive loss of skin turgor produce textural change, fine lines, and laxity that cannot be addressed by volume or by lifting alone. Skin quality is its own treatment domain. Resurfacing, skin boosters, retinoids, and collagen-stimulating biostimulators address this layer. It is worth assessing separately from volume and structural concerns, as patients often have needs across multiple domains simultaneously.
| Clinical principle Before selecting any treatment, identify which layer has aged most prominently in this patient. Filler addresses volume deficit and structural support. Surgical lifting addresses ligament laxity and positional change. No injectable will re-attach a descended malar fat pad. No amount of surgical lifting corrects skeletal resorption at the piriform or orbital rim. Matching treatment to pathology is the foundation of ethical and effective practice. |
A precise understanding of the scope of injectable treatment is the starting point for any patient assessment. Fitzgerald (2018), in a comprehensive review of structural facial rejuvenation with fillers, articulates the principle clearly: volume restoration starts from the skeletal framework and builds progressively to the soft tissue surface. This means that injectable correction can be remarkably effective when the underlying pathology is primarily volumetric — and progressively less effective as laxity and tissue displacement become the dominant features.
| Injectables address well | Injectables cannot adequately address |
| Volume deficit in the midface, temples, and periorbital region | Significant jowling with mandibular border disruption — requires structural lifting |
| Skeletal resorption at the maxilla, chin, and orbital rim — deep structural plane augmentation | Significant neck laxity — requires surgical platysmal work |
| Early nasolabial fold deepening from volume loss in the midface | Marked skin redundancy and excess — cannot be dissolved by volume |
| Congenital skeletal deficiency (weak chin, flat midface, recessed orbital rim) | Descended malar fat pad with marked nasolabial fold depth from ptosis |
| Static lines and skin quality concerns with low-viscosity or skin booster products | Significant brow ptosis requiring browlift (vs subtle neurotoxin repositioning for mild cases) |
| Early perioral volume loss and lip thinning | Lower eyelid laxity, tarsal ectropion — surgical domain |
| Mild-to-moderate ptotic change in an early presenter as a temporising measure | Platysmal banding and significant neck skin redundancy |
Certain clinical presentations are primarily structural and mechanical, and consistently produce better outcomes with surgery than with non-surgical techniques alone. The following signs, particularly in combination, indicate that a referral conversation or surgical pathway discussion should be part of the consultation:
There is a substantial and well-defined cohort of patients for whom injectable treatment is the correct first-line approach — patients in whom the dominant presentation is volumetric, structural, or early-stage laxity where the tissues remain sufficiently mobile and supported for filler to produce natural, lasting improvement. Fitzgerald and Graivier et al. (2010), in the published panel consensus on appropriate selection of non-surgical agents, emphasise the importance of identifying which patients are best served by injectables and which by surgery, and matching the treatment to the pathology.
| Presentation | Rationale for Injectable Approach |
| Early-to-moderate volume deficit in the midface with preserved soft tissue support | Deflation is the primary mechanism (Lambros, 2007). Restoring volume at the appropriate compartment level produces natural, lasting results without ligament attenuation. |
| Skeletal deficiency at the maxilla, orbital rim, or chin — congenital or age-related | Supraperiosteal structural filler directly addresses bony resorption (Mendelson & Wong, 2012). The correct treatment for the correct anatomical target. |
| Temple hollowing | Volume loss in the temporal fat compartment responds predictably to filler at the appropriate depth. No surgical equivalent for this zone. |
| Tear trough and periorbital hollowing without lower eyelid laxity | When the cause is volume loss rather than fat pseudoherniation or laxity, filler is the appropriate correction. Careful assessment of lower eyelid structure is essential before treating. |
| Early nasolabial fold deepening attributable to midface volume loss | Midface volumisation to restore the structural support for the nasolabial fold. Volume in the fold itself is secondary and often not required. |
| Early jowling in a younger patient with good skin tone | Structural mandibular filler can provide camouflage and modest improvement. Acknowledge this is temporising; refer if the patient’s goals or progression require lifting. |
| Lip thinning, perioral lines, marionette lines with minimal ptosis | Volume loss is the primary mechanism in the perioral region. Filler is the appropriate correction with careful product and plane selection. |
| Patients who explicitly prefer non-surgical outcomes or are not surgical candidates | Medical contraindications to surgery (anticoagulation, anaesthetic risk), patient preference for natural and subtle improvements, or specific patient goals that can be met with injectables — all are valid indications for non-surgical treatment even in those who might benefit from surgery. |
A crucial misconception in clinical practice is that surgical and non-surgical treatments are alternatives competing for the same patient. In reality, they address different pathologies within the same face. Fitzgerald and Graivier et al. (2010) are explicit on this point: as knowledge of facial ageing has increased, it has become increasingly apparent that surgical and injectable modalities are complementary, not mutually exclusive.
This is confirmed by practice data. Jacono et al. (2017), in a retrospective study of 157 patients who underwent facelift under the age of 50, found that these patients had begun non-surgical rejuvenation at an average age of 37 years — a full seven years before their eventual surgery. Patients reported that non-surgical treatments made them look four years younger; surgery subsequently made them look approximately ten years younger. Non-surgical treatment in the earlier years was not wasted — it was appropriate for the presenting pathology at that stage. The surgical indication emerged as laxity advanced.
Surgeons, too, rely on injectables: fillers and toxins used post-operatively maintain surgical results, address residual volume deficits not correctable at surgery, and treat the areas that surgery cannot reach. A well-planned facelift does not render injectables unnecessary; it changes which aspects of the face they are targeting.
Want to develop the facial assessment skills to identify surgical candidates, plan injectable treatment for the right patient, and understand where the two intersect? Explore our course range or join our next free webinar.
Every injector should have a clear approach to the referral conversation — both the clinical assessment that triggers it and the language used to raise it with patients.
| 📋 Clinical Features Warranting a Surgical Referral Discussion Moderate-to-severe jowling with disruption of the mandibular borderNeck laxity: loose skin, horizontal bands, platysmal bandingSignificant brow ptosis with lid hooding — beyond neurotoxin correctionDermatochalasis or significant upper eyelid skin redundancyMarked malar fat pad descent as the primary driver of nasolabial fold depthThe patient’s stated goals cannot realistically be achieved with injectablesHistory of repeated, incrementally escalating treatment with diminishing returnsPatient asks directly whether surgery would be betterPrior non-surgical treatment has produced an over-volumised or distorted appearance from attempting to compensate for structural laxity |
Many patients are relieved when an injector raises surgery as an option, because it validates their own privately held doubts about whether non-surgical treatment is giving them what they want. Framing the conversation around the patient’s goals rather than the inadequacy of injectables makes it easier:
| Avoid | Prefer |
| “Fillers won’t help you” | “Your primary concern is the jawline and neck definition, and the most effective way to address that fully is through a surgical consultation. I can continue to support your skin quality and volume in the meantime.” |
| “You need a facelift” | “Based on what I’m seeing, I think you’d benefit from a conversation with a facial plastic surgeon. That doesn’t mean you have to go ahead with anything, but it would give you the full picture.” |
| Proceeding with treatment and saying nothing | “I want to be honest with you about what injectables can and can’t achieve for your specific concerns.” |
| Over-promising surgical-level results from injectables | “I can improve volume and skin quality, and that will make a real difference. But if your goal is to address the neck and jowl area significantly, surgery would achieve more.” |
A referral is not a failure. It is evidence of clinical judgement and integrity. Patients who are appropriately referred and receive excellent surgical outcomes often return to the injector who referred them for ongoing non-surgical maintenance. Building relationships with facial plastic surgeons and oculoplastic surgeons locally ensures that patients are referred to practitioners they can trust, and that the clinical conversation is two-directional.
| Develop the Assessment Expertise to Treat the Right Patient in the Right Way Knowing when to inject and when to refer is one of the most advanced clinical skills in aesthetic medicine. At Acquisition Aesthetics, facial assessment, treatment planning, and patient communication are embedded across all levels of our training — from Foundation to Level 7 Diploma. Whether you’re building your practice or refining your clinical decision-making, our evidence-based curriculum develops the judgement that separates outstanding injectors from good ones. ➤ Explore Our Courses and Book Your Place |
Ready to Build the Clinical Expertise to Assess Every Patient?
| 📹 Book a Video Call Speak with Angharad or Violetta about which training level is right for you. Book a Call |
| 📋 Course Enquiry Questions about training content and what to expect at each level. Enquire Now |
| 💬 WhatsApp Message us directly — we’ll respond as soon as we can. WhatsApp Us |
🎓 Join our next free webinar — expert-led sessions on facial assessment, treatment planning, and advancing your aesthetic practice.
Fitzgerald R, Graivier MH, Kane M, et al.. Surgical versus nonsurgical rejuvenation.. Aesthet Surg J. 2010;30 Suppl:16S–19S.. PubMed
Fitzgerald R, Graivier MH, Kane M, et al.. Appropriate selection and application of nonsurgical facial rejuvenation agents and procedures: panel consensus recommendations.. Aesthet Surg J. 2010;30 Suppl:36S–45S.. PubMed
Fitzgerald R, Carqueville J, Yang PT.. An approach to structural facial rejuvenation with fillers in women.. Int J Womens Dermatol. 2018;5(1):52–67.. PubMed
Jacono AA, Malone MH, Lavin TJ.. Nonsurgical facial rejuvenation procedures in patients under 50 prior to undergoing facelift: habits, costs, and results.. Aesthet Surg J. 2017;37(4):448–453.. PubMed
Lambros V.. Observations on periorbital and midface aging.. Plast Reconstr Surg. 2007;120(5):1367–1376.. PubMed
Mendelson B, Wong CH.. Changes in the facial skeleton with aging: implications and clinical applications in facial rejuvenation.. Aesthetic Plast Surg. 2012;36(4):753–760.. PubMed
Sweis I, DeRoss L, Raman S, Patel P.. Potential effects of repetitive panfacial filler injections on facelift surgery and surgical outcomes: survey results of the members of the Aesthetic Society.. Aesthet Surg J Open Forum. 2023;5:ojad010.. PubMed
Tan S.. Surgical or nonsurgical facial rejuvenation: the patients’ choice.. Aesthet Surg J Open Forum. 2023;5:ojad075.. PubMed
